Brief: Longeveron Says Elpis I Met Its Primary Endpoint Of Safety Through 1-Year Post-Treatment
27/10/2024 19:12
Oct 27 (Reuters) - Longeveron Inc LGVN.O :
* LONGEVERON INC - ELPIS I MET ITS PRIMARY ENDPOINT OF
SAFETY
THROUGH 1-YEAR POST-TREATMENT
* LONGEVERON INC - ELPIS II PHASE 2B CLINICAL TRIAL IS
CURRENTLY
ONGOING
Source text: ID:nGNX2Mh199
Further company coverage: LGVN.O
((Reuters.Briefs@thomsonreuters.com;))